gmp-orphan ("GMPO") designs, develops and markets innovative patented drugs in life-threatening unmet medical rare diseases on the main regulated territories (US, EU, JP), based on already registered molecules (repositioning), using untapped academic research results. GMPO relies on a highly professional management team composed of three PharmD with proven track records in the pharmaceutical industry and as entrepreneurs, one Agronomist (INA) and one finance specialist (HEC). The development of molecules to treat rare diseases with a repositioning R&D strategy makes it possible to considerably reduce time to market and development costs while significantly increasing registration success rate.
View Top Employees from gmp-orphan SA ("GMPO")| Website | http://www.gmp-o.com |
| Revenue | $600000 |
| Employees | 5 (5 on RocketReach) |
| Founded | 2011 |
| Technologies |
JavaScript,
HTML,
PHP
+18 more
(view full list)
|
| Industry | Pharmaceuticals, Innovative drugs, Orphan drugs, Rare diseases |
Looking for a particular gmp-orphan SA ("GMPO") employee's phone or email?
gmp-orphan SA ("GMPO") Questions
The gmp-orphan SA ("GMPO") annual revenue was $600000 in 2023.
Peter Vu is the Director of Global Commercial Operations of gmp-orphan SA ("GMPO").
5 people are employed at gmp-orphan SA ("GMPO").
gmp-orphan SA ("GMPO") is based in Paris, Ile-De-France.
Top gmp-orphan SA ("GMPO") Employees
